NASDAQ:RAIN

Rain Therapeutics Stock Insider Trading

> Biotechnology

Buy RAIN

*Your capital is at risk

$2.21

-0.115 (-4.96%)

At Close: Jun 03, 2026

Rain Therapeutics Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 82.44. In total, the insiders bought 1.25M and sold 20.25M RAIN shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	82.44
● Buy	1.25M shares
● Sell	20.25M shares
10% Buy Activity Negligible or No Correlation
Sell Signal Low Confidence Feb 17, 2026 Analysis Breakdown: Signal is highly questionable due to a strongly contradictory positive Insider Power Score of 82.44. Confidence increased due to high data reliability score of 80. Supported by overwhelming sell-side pressure (10% buys).

Historical Insider Trades

Date	Type	Person	Role	Amount
Dec 22, 2025 Buy	Common Stock J-Other	Sylvester David C	Director	0 Value: $0
Sep 12, 2025 Sell	Class A Common Stock S-Sale	Dickerson Lyman B Director	Director	4 787 Value: $27.7K
Sep 12, 2025 Sell	Class A Common Stock S-Sale	Dickerson Lyman B Director	Director	4 787 Value: $27.7K
Sep 11, 2025 Sell	Class A Common Stock S-Sale	Dickerson Lyman B Director	Director	398 Value: $2K
Sep 11, 2025 Sell	Class A Common Stock S-Sale	Dickerson Lyman B Director	Director	398 Value: $2K
Sep 10, 2025 Sell	Class A Common Stock S-Sale	Dickerson Lyman B Director	Director	215 Value: $1K
Sep 10, 2025 Sell	Class A Common Stock S-Sale	Dickerson Lyman B Director	Director	215 Value: $1K
Sep 09, 2025 Sell	Class A Common Stock S-Sale	Dickerson Lyman B Director	Director	1 917 Value: $10.0K
Sep 09, 2025 Sell	Class A Common Stock S-Sale	Dickerson Lyman B Director	Director	1 917 Value: $10.0K
Sep 05, 2025 Buy	Class A Common Stock A-Award	Seidl Randy Chief Executive Officer	CEO / President	602 320 Value: $2.65M
Sep 05, 2025 Buy	Class A Common Stock A-Award	Seidl Randy Chief Executive Officer	CEO / President	602 320 Value: $2.65M
May 22, 2025 Buy	Class A Common Stock P-Purchase	Seidl Randy Chief Executive Officer	CEO / President	4 000 Value: $10.3K
May 21, 2025 Buy	Class A Common Stock P-Purchase	Seidl Randy Chief Executive Officer	CEO / President	30 000 Value: $75.9K
May 20, 2025 Buy	Class A Common Stock P-Purchase	Seidl Randy Chief Executive Officer	CEO / President	8 514 Value: $14.7K
Apr 01, 2025 Buy	Common Stock J-Other	Reardon Robert	Director	0 Value: $0
Apr 01, 2025 Buy	Common Stock J-Other	Reardon Robert	Director	0 Value: $0
Apr 01, 2025 Buy	Common Stock J-Other	Peperzak Marcus	Director	0 Value: $0
Apr 01, 2025 Buy	Common Stock J-Other	Peperzak Marcus	Director	0 Value: $0
Jan 26, 2024 Sell	Common Stock U-Tender	Tang Kevin C 10 Percent Owner	10% Owner	3 850 513 Value: $4.47M
Jan 26, 2024 Sell	Common Stock U-Tender	Tang Kevin C 10 Percent Owner	10% Owner	3 850 513 Value: $4.47M
Jan 26, 2024 Sell	Stock Option (Right to Buy) D-Return	Bvf Partners L P/il See Remarks; Former 10% Owner	Director	35 000 Value: $42.4K
Jan 26, 2024 Sell	Stock Option (Right to Buy) D-Return	Bvf Partners L P/il See Remarks; Former 10% Owner	Director	20 000 Value: $48.8K
Jan 26, 2024 Sell	Stock Option (Right to Buy) D-Return	Bvf Partners L P/il See Remarks; Former 10% Owner	Director	20 000 Value: $48.8K
Jan 26, 2024 Sell	Stock Option (Right to Buy) D-Return	Bvf Partners L P/il See Remarks; Former 10% Owner	Director	35 000 Value: $42.4K
Jan 26, 2024 Sell	Stock Option (Right to Buy) D-Return	Wolff Stefani Director	Director	35 000 Value: $42.4K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT RAIN THERAPEUTICS INC.

Rain Therapeutics Inc., a clinical-stage precision oncology company, engages in developing therapies that target oncogenic drivers in the United States. Its lead product candidate is milademetan, a small molecule oral inhibitor of mouse double minute 2, which is oncogenic in various cancers. The company is also developing milademetan which is in Phase 3 clinical trial for liposarcoma, Phase II clinical trial for solid tumors, and Phase II clinica...

Read Full Profile Here